# Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia

> **NCT07297550** · PHASE1,PHASE2 · NOT_YET_RECRUITING · sponsor: **Institute of Hematology & Blood Diseases Hospital, China** · enrollment: 42 (estimated)

## Conditions studied

- Severe Aplastic Anemia
- Refractory Aplastic Anemia
- Newly Diagnosed Aplastic Anemia

## Interventions

- **DRUG:** Golidocitinib Capsules

## Key facts

- **NCT ID:** NCT07297550
- **Lead sponsor:** Institute of Hematology & Blood Diseases Hospital, China
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2025-12-15
- **Primary completion:** 2026-12-31
- **Final completion:** 2027-07-01
- **Target enrollment:** 42 (ESTIMATED)
- **Last updated:** 2025-12-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07297550

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07297550, "Safety and Efficacy of the JAK1 Inhibitor Combined With Intensive Immunosuppressive Therapy in Severe Aplastic Anemia". Retrieved via AI Analytics 2026-06-09 from https://api.ai-analytics.org/clinical/NCT07297550. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*